{
    "clinical_study": {
        "@rank": "93961", 
        "arm_group": [
            {
                "arm_group_label": "amdoxovir 300 mg bid", 
                "arm_group_type": "Experimental", 
                "description": "in combination with zidovudine 300 mg bid and lopinavir/ritonavir (400 mg/100 mg bid) for 36 weeks."
            }, 
            {
                "arm_group_label": "amdoxovir 500 mg bid", 
                "arm_group_type": "Experimental", 
                "description": "in combination with zidovudine 300 mg bid and lopinavir/ritonavir (400 mg/100 mg bid) for 36 weeks."
            }
        ], 
        "brief_summary": {
            "textblock": "This study is an open-label extension of RFSP-AMDX-2010 study for those subjects who\n      received treatment with amdoxovir (300 mg or 500 mg twice daily) for 12 weeks and benefited\n      from it. This study will examine the safety and efficacy of the investigational HIV drug,\n      amdoxovir (300 mg and 500 mg bid doses; N = up to 30) in combination with zidovudine and\n      lopinavir/ritonavir for 36 weeks.\n\n      Subjects will continue to receive either amdoxovir 300 mg twice daily  or amdoxovir 500 mg\n      twice daily, each in combination with zidovudine 300 mg twice daily and lopinavir/ritonavir\n      (400 mg/100 mg twice daily) for additional 36 weeks."
        }, 
        "brief_title": "A Safety and Efficacy Study of Amdoxovir in HIV-1 Treatment-experienced Subjects", 
        "completion_date": {
            "#text": "October 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Human Immunodeficiency Virus Infection", 
        "condition_browse": {
            "mesh_term": [
                "Acquired Immunodeficiency Syndrome", 
                "HIV Infections", 
                "Immunologic Deficiency Syndromes", 
                "Virus Diseases"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Must have completed Study RFSP-AMDX-2010 and received treatment with amdoxovir (500\n             mg bid or 300 mg bid) for 12 weeks before entry into study RFSP-AMDX-2012.\n\n          -  Must have maintained \u2265 1.0 log10 copies/mL from baseline at Week 12 in Study\n             RFSP-AMDX-2010.\n\n          -  Must not have had any serious adverse experience since enrollment in Study\n             RFSP-AMDX-2010, whether or not considered to be study drug-related.\n\n        Exclusion Criteria:\n\n          -  Subjects who require ongoing therapy of nephrotoxic drugs or competitors of renal\n             excretion.\n\n          -  Subjects who require therapy with hematologic, bone marrow suppressive or   cytotoxic\n             agents.\n\n          -  Subjects who require medications that are highly dependent on CYP3A for clearance and\n             for which elevated plasma concentrations are associated with life-threatening adverse\n             events.\n\n          -  Known allergy/sensitivity or any hypersensitivity to components of study drugs or\n             their formulations.\n\n          -  Women who are pregnant or breastfeeding."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "0", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "November 28, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01738555", 
            "org_study_id": "RFSP-AMDX-2012"
        }, 
        "intervention": [
            {
                "arm_group_label": "amdoxovir 300 mg bid", 
                "description": "2 x 150 mg capsules bid", 
                "intervention_name": "amdoxovir 300 mg bid", 
                "intervention_type": "Drug", 
                "other_name": [
                    "DAPD", 
                    "AMDX"
                ]
            }, 
            {
                "arm_group_label": "amdoxovir 500 mg bid", 
                "description": "2 x 250 mg capsules bid", 
                "intervention_name": "amdoxovir 500 mg bid", 
                "intervention_type": "Drug", 
                "other_name": [
                    "DAPD", 
                    "AMDX"
                ]
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Zidovudine", 
                "Lopinavir"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "amdoxovir", 
            "zidovudine", 
            "HIV", 
            "HAART", 
            "antiretroviral"
        ], 
        "lastchanged_date": "March 27, 2013", 
        "number_of_arms": "2", 
        "official_title": "An Open-label, 36-week Extension Study on Amdoxovir at 500 mg Bid or 300 mg Bid in Combination With Zidovudine and Lopinavir/Ritonavir in HIV-1 Treatment-experienced Subjects With M184I/V Mutation in Addition to 0-2 Confirmed Thymidine Analog Mutations.", 
        "overall_official": {
            "affiliation": "RFS Pharma, LLC", 
            "last_name": "Luz Pascual, MD MPH", 
            "role": "Study Director"
        }, 
        "overall_status": "Withdrawn", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "Argentina: ANMAT (Administraci\u00f3n Nacional de Medicamentos, Alimentos y Tecnolog\u00eda M\u00e9dica)"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "August 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "HIV-1 viral load", 
            "safety_issue": "No", 
            "time_frame": "up to  48 Weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01738555"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Incidence of adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "up to  48 Weeks"
            }, 
            {
                "measure": "Changes in Immunologic Function (CD4 cell counts)", 
                "safety_issue": "No", 
                "time_frame": "from baseline to Weeks 18, 24, 30, 36, 42, 48"
            }
        ], 
        "source": "RFS Pharma, LLC", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "RFS Pharma, LLC", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2013"
    }
}